Biphasic dissolution method for quality control and assurance of drugs containing active substances in the form of weak acid salts
By: Aleš Franc, Jan Muselłk, Roman Goněc and David Vetchý
References
- 1, USP Convention, Rockville (MD) 2015, p. 3869.
- 2. S. Klein, The use of biorelevant dissolution media to forecast the in vivo performance of a drug,(2010) 397–406; DOI: 10.1208/s12248-010-9203-3.
- 3. Y. Qiu, Y. Chen, G. Zhang and W. Porter,, Academic Press, London 2009, p. 411.
- 4. Sirius Analytical Instruments Ltd., New instrument for automated biorelevant biphasic dissolution and solubility testing,October 2013;; last access date September 24, 2015.
- 5. A. Franc and J. Muselik,Pat. CZ304136-B6, October 2013.
- 6. J. Muselik, A. Franc, P. Dolezel, R. Gonec, A. Krondlova and I. Lukasova, Influence of process parameters on content uniformity of a low dose active pharmaceutical ingredient in a tablet formulation according to GMP,(2014) 355–367; DOI: 10.2478/ACPH-2014-0022.
- 7. L. M. Vercaigne and G. G. Zhanel, Clinical significance of bioequivalence and interchangeability of narrow therapeutic range drugs: focus on warfarins,(1998) 92–94.
- 8. V. R. S. Uppoor, Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations,(2001) 127–132; DOI: 10.1016/S0168-3659(01)00268-1.
Language: English
Page range: 139 - 145
Accepted on: Sep 29, 2015
Published on: Mar 7, 2016
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2016 Aleš Franc, Jan Muselłk, Roman Goněc, David Vetchý, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.